Complix N.V.
PrivateLast Round
Grant
Oct 7, 2020
Total Funding Raised
$34.98M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Complix N.V. operates in Healthcare & Life Sciences and is based in Diepenbeek. Its latest recorded funding round was a Grant round in October 2020.
Complix N.V. is a biopharmaceutical company that develops a pipeline of transformative Cell Penetrating Alphabody (CPAB) based biotherapeutics for challenging intracellular targets in cancer and autoimmune diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Complix N.V. Comparables
Compare Complix N.V. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Confo Therapeutics | 77% | |
| Affibody AB | 74% | |
| Sanofi | 69% |
For institutional investors. Book with your work email.
Complix N.V. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Oct 7, 2020 | ||||
| Grant | Dec 14, 2017 | ||||
| Series B | Jun 26, 2013 | ||||
| Grant | Oct 30, 2012 | ||||
| Series A | Jan 14, 2011 | ||||
Series A | Jun 9, 2010 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Complix N.V. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| LRM | Series B, VC Round, Series A |
| Vinnof Fund | Series B, Seed |
| TrustCapital | Series B |
| Gimv | Series B |
| KU Leuven Research & Development (LRD) | Series B |
| Andera Partners | Series B |
| Vesalius Biocapital Partners | Series B, VC Round, Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors grew 432% MoM, from 323 to 1.7K.
- Jun 26, 2013
$16M round led by Gimv.
For institutional investors. Book with your work email.
Complix N.V. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Complix N.V.'s valuation, stock price, and market status.
Is Complix N.V. a public or private company?
Complix N.V. is a private company.
What is the current stock price of Complix N.V.?
Complix N.V. is a private company, so its shares have no public market price. Caplight tracks Complix N.V.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Complix N.V. worth (valuation)?
Valuation information for Complix N.V. is not publicly available.
Can I buy Complix N.V. stock?
Complix N.V. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Complix N.V.'s last funding round?
Complix N.V.'s most recent funding round was Grant on October 7, 2020.
Who are the main investors in Complix N.V.?
Key investors in Complix N.V. include LRM, Andera Partners, Vesalius Biocapital Partners, VLAIO, PMV.
Will Complix N.V. IPO soon?
No public IPO plans have been announced for Complix N.V..
How can I track Complix N.V. secondary market activity?
Caplight tracks bids, offers, and trades in Complix N.V.'s shares on secondary markets.